Overview
- Q4 revenue rose 10% to $35.7 million and transition-period revenue reached $75.5 million, as gross margin improved to 31% and quarterly adjusted EBITDA hit $8.6 million with year-end liquidity around $39 million.
- Operating discipline continued with six straight quarters of lower operating expenses, a fourth consecutive quarter of positive operating cash flow, and $3.6 million of free cash flow over the seven-month transition.
- For 2026, Lifecore guided to $120–125 million in revenue, adjusted EBITDA of $20.5–25 million, and a net loss of $28.9–33.4 million, which William Blair said implies a 12%–15% revenue decline versus 2025 levels.
- Management cited three headwinds shaping 2026: the loss of a customer after a supply strategy shift, a temporary demand dip as a key customer built excess hyaluronic acid inventory in 2025 ahead of 2027 aseptic volumes, and a delayed 2026 launch due to customer funding constraints.
- Quarterly growth was driven by a $5.6 million increase in hyaluronic acid manufacturing tied to the largest customer, while CDMO revenue fell $2.4 million on the absence of take-or-pay revenue and lower aseptic volumes, and analysts noted commercialization timelines sliding to 2027–2030.